Study #2024-0442
A multicenter, open-label, phase 1 study of AJ1-11095 administered as oral monotherapy in patients with primary myelofibrosis (pmf), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have been failed by a Type I JAK2 Inhibitor (JAK2i)
MD Anderson Study Status
Enrolling
Treatment Agent
LY5830966
Description
J8G-MC-JDIA (AJX-101) is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II Janus Kinase 2 (JAK2) inhibitor, LY5830966, in participants with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Primary Myelofibrosis
Study phase:
Phase I
Physician name:
Prithviraj Bose
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.